Upload your Marketing & Sales content on your company Virtual Booth, click HERE.
Details:
EA-114 (fulvestrant) is an estrogen receptor antagonist, which being developed for hormone-receptor-positive (HR+) metastatic breast cancer and company plans to file a new drug application for EA-114 in 2024
Lead Product(s): Fulvestrant
Therapeutic Area: Oncology Product Name: EA-114
Highest Development Status: Phase IIIProduct Type: Small molecule
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable August 29, 2023
Details:
CAL02 is an investigational, innovative, first-in-class anti-infective agent that acts as a competitive decoy, or lure, for bacterial virulence factors, which contribute to infection-related complications, sepsis, septic shock, and death.
Lead Product(s): CAL02
Therapeutic Area: Infections and Infectious Diseases Product Name: CAL02
Highest Development Status: Phase IIProduct Type: Small molecule
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable July 24, 2023
Details:
CAL02 is an investigational, innovative, first-in-class anti-infective agent that acts as a competitive decoy, or lure, for bacterial virulence factors, which contribute to infection-related complications, sepsis, septic shock, and death.
Lead Product(s): CAL02
Therapeutic Area: Infections and Infectious Diseases Product Name: CAL02
Highest Development Status: Phase IIProduct Type: Small molecule
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable June 14, 2023
Details:
Under the settlement agreement, Dr. Reddy’s has the right to market its product BENDEKA® (bendamustine hydrochloride), an alkylating drug, indicated for treatment of patients with Chronic lymphocytic leukemia.
Lead Product(s): Bendamustine Hydrochloride
Therapeutic Area: Oncology Product Name: Bendeka
Highest Development Status: ApprovedProduct Type: Small molecule
Partner/Sponsor/Collaborator: Dr. Reddy\'s Laboratories
Deal Size: Undisclosed Upfront Cash: Undisclosed
Deal Type: Agreement April 05, 2023
Details:
PEMFEXY® (pemetrexed injection) in combination with pembrolizumab and platinum chemotherapy for the initial treatment of patients with metastatic, non-squamous, non-small cell lung cancer (“NSCLC”) with no EGFR or ALK genomic tumor aberrations.
Lead Product(s): Pemetrexed,Pembrolizumab
Therapeutic Area: Oncology Product Name: Pemfexy
Highest Development Status: ApprovedProduct Type: Small molecule
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable December 19, 2022
Details:
CAL02, a novel first-in-class broad-spectrum anti-virulence agent for the adjunct treatment of severe community-acquired bacterial pneumonia, is being developed as an adjunct to the clinically indicated antibiotic treatment.
Lead Product(s): CAL02
Therapeutic Area: Pulmonary/Respiratory Diseases Product Name: CAL02
Highest Development Status: Phase IProduct Type: Large molecule
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable November 14, 2022
Details:
CAL02, a novel first-in-class broad-spectrum anti-virulence agent for the treatment of severe community-acquired bacterial pneumonia,is being developed as an add-on to the clinically indicated antibiotic treatment.
Lead Product(s): CAL02
Therapeutic Area: Infections and Infectious Diseases Product Name: CAL02
Highest Development Status: Phase IProduct Type: Large molecule
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable October 12, 2022
Details:
ENA-001, is a one-of-a-kind new chemical entity (NCE) designed as an agnostic respiratory stimulant. The compound has a novel mechanism of action that affects ventilation via the peripheral chemoreceptor pathways in the carotid body.
Lead Product(s): ENA-001
Therapeutic Area: Sleep Product Name: ENA-001
Highest Development Status: PreclinicalProduct Type: Small molecule
Partner/Sponsor/Collaborator: Enalare Therapeutics
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable October 03, 2022
Details:
With the acquisition, addition of the two products expands the presence in acute care space, BARHEMSYS® (amisulpride for injection) and BYFAVO® (remimazolam for injection) join Eagle portfolio.
Lead Product(s): Amisulpride
Therapeutic Area: Gastroenterology Product Name: Barhemsys
Highest Development Status: ApprovedProduct Type: Small molecule
Recipient: Acacia Pharma
Deal Size: $182.4 million Upfront Cash: $78.5 million
Deal Type: Acquisition June 09, 2022
Details:
Submission seeks approval for LDLL600 (landiolol) for the short-term reduction of ventricular rate in patients with supraventricular tachycardia, including atrial fibrillation and atrial flutter.
Lead Product(s): Landiolol Hydrochloride
Therapeutic Area: Cardiology/Vascular Diseases Product Name: LDLL600
Highest Development Status: Phase IIIProduct Type: Small molecule
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable June 01, 2022